|
MJsHusband
Exciting results have come from studies of multitargeted tyrosine kinase inhibitors, "small" molecules that act on multiple receptors in the cancerous cells, like Tykerb. Unlike (reversible) Herceptin, which only goes after the Her2 gene, also known as epidermal growth factor receptor (EGFR) type 2, (irreversible) Tykerb goes after Her1 (EGFR) but also Her2 (EGFR type 2). Tykerb irreversibly binds to EGFR and Her2. It works by blocking these receptors, preventing their activation and hopefully inhibiting the unwanted signaling pathways. And Tykerb is a BBB crossing drug.
Best wishes to MJ
Greg
|